Stay updated with breaking news from Esmo Congress. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FDA grants fast-track status to BNT325/DB-1305 for patients with platinum-resistant ovarian epithelial, fallopian tube, or primary peritoneal cancer.
The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy improved pathologic complete responses in key subsets of patients with early-stage, high-risk, estrogen receptor–positive/HER2-negative breast cancer enrolled in the phase 3 KEYNOTE-756 trial.
Bradley A. McGregor, MD, expands on the feasibility and safety considerations addressed through the design and methodology of the DAD study; highlights dose-limiting toxicities and early responses seen with sacituzumab govitecan plus enfortumab vedotin in treatment-resistant mUC; and explains how these results support further investigation of other ADC doublets.
Peter Schmid, FRCP, MD, PhD, discusses the evaluation of combination of the datopotamab deruxtecan and durvalumab in patients with first-line triple-negative breast cancer, details safety and efficacy findings derived from the combination in the BEGONIA trial, and highlights ongoing efforts with this combination.
Expert oncologist Benjamin Levy, MD, shares data from the LIBRETTO-431 trial comparing selpercatinib to chemotherapy plus pembrolizumab in RET fusion-positive NSCLC following ESMO 2023.